Structure Therapeutics Statistics
Total Valuation
GPCR has a market cap or net worth of $3.52 billion. The enterprise value is $2.06 billion.
| Market Cap | 3.52B |
| Enterprise Value | 2.06B |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GPCR has 71.07 million shares outstanding. The number of shares has increased by 13.80% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 71.07M |
| Shares Change (YoY) | +13.80% |
| Shares Change (QoQ) | +14.28% |
| Owned by Insiders (%) | 3.54% |
| Owned by Institutions (%) | 81.42% |
| Float | 54.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 70.32 |
| PB Ratio | 2.43 |
| P/TBV Ratio | 2.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.16, with a Debt / Equity ratio of 0.00.
| Current Ratio | 26.16 |
| Quick Ratio | 25.59 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.00% and return on invested capital (ROIC) is -12.03%.
| Return on Equity (ROE) | -15.00% |
| Return on Assets (ROA) | -11.57% |
| Return on Invested Capital (ROIC) | -12.03% |
| Return on Capital Employed (ROCE) | -14.45% |
| Weighted Average Cost of Capital (WACC) | -4.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$731,060 |
| Employee Count | 233 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GPCR has paid $607,000 in taxes.
| Income Tax | 607,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +177.92% in the last 52 weeks. The beta is -1.57, so GPCR's price volatility has been lower than the market average.
| Beta (5Y) | -1.57 |
| 52-Week Price Change | +177.92% |
| 50-Day Moving Average | 45.82 |
| 200-Day Moving Average | 51.86 |
| Relative Strength Index (RSI) | 51.88 |
| Average Volume (20 Days) | 577,350 |
Short Selling Information
The latest short interest is 6.21 million, so 11.97% of the outstanding shares have been sold short.
| Short Interest | 6.21M |
| Short Previous Month | 6.13M |
| Short % of Shares Out | 11.97% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -219.88M |
| Pretax Income | -169.73M |
| Net Income | -170.34M |
| EBITDA | -207.99M |
| EBIT | -209.63M |
| Earnings Per Share (EPS) | -$2.70 |
Balance Sheet
The company has $1.46 billion in cash and $5.79 million in debt, with a net cash position of $1.45 billion or $20.44 per share.
| Cash & Cash Equivalents | 1.46B |
| Total Debt | 5.79M |
| Net Cash | 1.45B |
| Net Cash Per Share | $20.44 |
| Equity (Book Value) | 1.45B |
| Book Value Per Share | 20.36 |
| Working Capital | 1.43B |
Cash Flow
In the last 12 months, operating cash flow was -$154.74 million and capital expenditures -$4.48 million, giving a free cash flow of -$159.22 million.
| Operating Cash Flow | -154.74M |
| Capital Expenditures | -4.48M |
| Depreciation & Amortization | 1.99M |
| Net Borrowing | n/a |
| Free Cash Flow | -159.22M |
| FCF Per Share | -$2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GPCR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.80% |
| Shareholder Yield | -13.80% |
| Earnings Yield | -4.84% |
| FCF Yield | -4.53% |
Analyst Forecast
The average price target for GPCR is $104.83, which is 111.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $104.83 |
| Price Target Difference | 111.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |